Clinical Trial Detail

NCT ID NCT04026412
Title A Study of Nivolumab and Ipilimumab in Untreated Patients With Stage 3 NSCLC That is Unable or Not Planned to be Removed by Surgery (CheckMate73L)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

lung non-small cell carcinoma

Therapies

Nivolumab

Ipilimumab + Nivolumab

Durvalumab

Age Groups: senior adult

No variant requirements are available.